Chemotherapy and antibody therapy for relapsed Hodgkin lymphoma post-ASCT.
| Agent (reference) . | Number treated . | Prior ASCT . | Response . | PFS, mo . |
|---|---|---|---|---|
| Abbreviations: ASCT, autologous stem cell transplantation; PFS, progression-free survival; m, months; NS, not stated; CHL classical Hodgkin lymphoma; NLPHL, nodular lymphocyte predominant Hodgkin lymphoma. | ||||
| Vinblastine26 | 17 | 17 | 10/17 | 8 |
| Vinorelbine27 | 24 | NS | 11/24 | — |
| Gemcitabine28 | 27 | 18 | 6/27 | 6 |
| Vinorelbine + gemcitabine29 | 8 | NS | 6/8 | NS |
| Rituximab | ||||
| CHL30 | 22 | 18 | 5/22 | — |
| NLPHL31 | 15 | 2 | 14/15 | 33 |
| Rituximab + gemcitabine32 | 33 | 18 | 16/33 | 3 |
| Bortezomib33 | 14 | 13 | 1/14 | NS |
| Bortezomib34 | 30 | 19 | 0/30 | 1.4 |
| Bortezomib35 | 12 | NS | 0/12 | NS |
| Agent (reference) . | Number treated . | Prior ASCT . | Response . | PFS, mo . |
|---|---|---|---|---|
| Abbreviations: ASCT, autologous stem cell transplantation; PFS, progression-free survival; m, months; NS, not stated; CHL classical Hodgkin lymphoma; NLPHL, nodular lymphocyte predominant Hodgkin lymphoma. | ||||
| Vinblastine26 | 17 | 17 | 10/17 | 8 |
| Vinorelbine27 | 24 | NS | 11/24 | — |
| Gemcitabine28 | 27 | 18 | 6/27 | 6 |
| Vinorelbine + gemcitabine29 | 8 | NS | 6/8 | NS |
| Rituximab | ||||
| CHL30 | 22 | 18 | 5/22 | — |
| NLPHL31 | 15 | 2 | 14/15 | 33 |
| Rituximab + gemcitabine32 | 33 | 18 | 16/33 | 3 |
| Bortezomib33 | 14 | 13 | 1/14 | NS |
| Bortezomib34 | 30 | 19 | 0/30 | 1.4 |
| Bortezomib35 | 12 | NS | 0/12 | NS |